Jann, M.W. (2000) Rivastigmine, a New-Generation Cholinesterase Inhibitor for the Treatment of Alzheimer’s Disease. Pharmacotherapy, 20, 1-12. - References

Journals by Subject

Publish with us

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Article citationsMore>>

Jann, M.W. (2000) Rivastigmine, a New-Generation Cholinesterase Inhibitor for the Treatment of Alzheimer’s Disease. Pharmacotherapy, 20, 1-12. http://dx.doi.org/10.1592/phco.20.1.1.34664

has been cited by the following article:

Open Access

Articles

Risperidone Versus Yokukansan in the Treatment of Severe Alzheimer’s Disease

Yuko Furuhashi, Kouichi Shin

International Journal of Clinical Medicine Vol.2 No.2, May 27, 2011

DOI: 10.4236/ijcm.2011.22028
Open Access

Articles

Arginase as a Potential Target in the Treatment of Alzheimer’s Disease

Baruh Polis, Abraham O. Samson

Advances in Alzheimer's Disease Vol.7 No.4, November 22, 2018

DOI: 10.4236/aad.2018.74009
Open Access

Articles

The Growing Evidence for Photobiomodulation as a Promising Treatment for Alzheimer’s Disease

Lew Lim

Journal of Biosciences and Medicines Vol.6 No.12, December 27, 2018

DOI: 10.4236/jbm.2018.612010
Open Access

Articles

Dementia and Cognitive Impairment Reduction after Laser Transcatheter Treatment of Alzheimer’s Disease

Ivan V. Maksimovich

World Journal of Neuroscience Vol.5 No.3, June 5, 2015

DOI: 10.4236/wjns.2015.53021
Open Access

Articles

Analysis of Technological Developments in the Treatment of Alzheimer’s Disease through Patent Documents

Karinne Marieta Carvalho, Eduardo Winter, Adelaide Maria de Souza Antunes

Intelligent Information Management Vol.7 No.5, September 29, 2015

DOI: 10.4236/iim.2015.75022

Follow SCIRP

	+1 323-425-8868
	customer@scirp.org
	+86 18163351462(WhatsApp)
	1655362766

	Paper Publishing WeChat

Journals by Subject

Publish with us

Article citationsMore>>

Home

About SCIRP

Service

Policies